10-Q: Vicarious Surgical Reports Q1 2025 Results Amidst NYSE Listing Concerns and Ongoing Development

Vicarious Surgical faces NYSE compliance issues and continues product development with a net loss of $15.39 million for Q1 2025.

Summary

• Vicarious Surgical reported a net loss of $15.39 million for the three months ended March 31, 2025, compared to a net loss of $17.00 million for the same period in 2024.
• The company is pre-revenue and is focused on developing its surgical robotic system.
• Operating expenses decreased slightly by 2% year-over-year, primarily due to lower personnel-related expenses.
• The company is addressing a notice from the NYSE regarding non-compliance with continued listing standards due to its market capitalization falling below $50 million.
• As of March 31, 2025, Vicarious Surgical had cash, cash equivalents, and short-term investments totaling $37.36 million.
• The company anticipates needing additional funding to continue operations and is exploring financing options.
• There is substantial doubt about the company's ability to continue as a going concern based on its current cash position.
• The company is working to remediate material weaknesses in its internal control over financial reporting.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the company's financial losses, going concern uncertainty, NYSE listing compliance issues, and material weaknesses in internal control. While there are some positive aspects, the overall outlook is challenging.

Positives

• The net loss decreased from $17.00 million in Q1 2024 to $15.39 million in Q1 2025.
• Operating expenses saw a slight decrease of 2% year-over-year.
• The company is actively pursuing additional equity or debt financing to address its capital needs.
• The company is taking steps to remediate material weaknesses in internal control over financial reporting.

Negatives

• The company is pre-revenue and has an accumulated deficit of $211.33 million.
• The company received a notice from the NYSE regarding non-compliance with continued listing standards.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company identified material weaknesses in its internal control over financial reporting.

Risks

• The company's ability to continue as a going concern is dependent on raising additional capital.
• Failure to comply with NYSE listing standards could lead to delisting and adverse consequences for the company and its stockholders.
• The company has not yet received FDA authorization for its surgical robotic system.
• The company faces risks related to product development, regulatory approval, competition, and economic conditions.
• The company's future capital requirements are subject to various factors, including clinical trial outcomes and market authorization timing.

Future Outlook

The company expects to continue incurring net losses as it invests in commercialization and new product development. It anticipates needing additional funding to complete clinical trials, obtain market authorization, and commercialize its surgical system. The company expects that its cash, cash equivalents and short-term investments will be sufficient to support its operations into the first quarter of 2026.

Management Comments

• Management believes that the information provided is relevant to an assessment and understanding of the company's results of operations and financial condition.
• Management does not believe that the company's cash, cash equivalents and short-term investments balance at March 31, 2025 of $37,362 will be sufficient to support our operations for the next 12 months from the date of issuance of these financial statements, and accordingly, this raises substantial doubt about our ability to continue as a going concern.

Industry Context

The company is developing a surgical robotic system to address the limitations of open surgery and existing robot-assisted surgical approaches. The company estimates a large addressable market of over 45 million soft tissue surgical procedures annually worldwide.

Comparison to Industry Standards

• The document does not provide enough information to make a detailed comparison to industry standards.
• Without specific benchmarks or competitor data, it's difficult to assess Vicarious Surgical's performance relative to companies like Intuitive Surgical (ISRG) or Medtronic (MDT) in terms of R&D spending, sales efficiency, or cash burn rate.
• A more detailed analysis would require comparing Vicarious Surgical's technology and clinical trial progress to other players in the surgical robotics space, as well as evaluating its financial metrics against industry averages for similar-stage companies.

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings and the risk of delisting from the NYSE.
• Employees face uncertainty due to the company's financial situation and potential need for cost-cutting measures.
• Customers (hospitals and surgeons) face uncertainty regarding the availability and reliability of the company's surgical robotic system.
• Suppliers and creditors face increased risk of non-payment due to the company's financial challenges.

Next Steps

• The company intends to submit a plan to the NYSE to regain compliance with continued listing standards.
• The company will continue to pursue additional equity or debt financing.
• The company will continue to work on remediating material weaknesses in its internal control over financial reporting.
• The company plans to file a de novo application with the FDA for use in ventral hernia procedures as its first indication.

Key Dates

Keywords

Vicarious Surgical, surgical robotics, NYSE compliance, financial results, Form 10-Q, going concern, net loss, R&D expenses, FDA authorization, internal control, warrant liabilities